Interview with Marco Caligiuri, Country Manager, Celgene Turkey
What were the first challenges you have faced as the new General Manager of Celgene turkey? In all humility, I have to say that even though it is always challenging…
Address: Celgene Türkiye
Büyükdere Cad. N:103
Şarlı İş Merkezi B Blok Daire:3
34394 Mecidiyeköy, İstanbul,Turkey
Tel: +90 212 354 1806
Web: http://www.celgene.com.tr/
Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide.
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin’s lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer.
Celgene Turkey operates in Turkey since March 2008.
What were the first challenges you have faced as the new General Manager of Celgene turkey? In all humility, I have to say that even though it is always challenging…
Consumer healthcare products manufacturer Winalite is working to penetrate the Turkish market, but with regulations complicating bringing their portfolio from China, general manager Arafat Yadigar is looking to develop a…
Ozgur Tomruk, J&J’s Managing Director for Global Surgery talks about Turkey’s importance for the company, the priorities they have set, J&J’s commitment to quality and his ambition for the company’s…
Nil Tunaşar, managing partner of Transorient, discusses significance of tracking performance metrics among 3PL providers, the organization’s technology overhaul, and also highlights the type of logistics solutions encompassed under Transorient’s…
Matthias Diewald (MD) and Asli Volkan (AV) elaborate on HELM Kimya’s longstanding presence within Turkey and the type of market opportunities available for co-development and contract manufacturing. They also explain the…
Haluk Ataoglu, academic turned founder of Matriks Biotek®, talks about his aspirations for his company and the Turkish R&D landscape as well as how to penetrate the global pharmaceutical market…
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
BMS Turkey’s new general manager discusses Opdivo (nivolumab) their revolutionary new product for squamous non-small cell lung cancer, their registry of 1200 patients in Turkey with melanoma, potential developments in pharmaceutical…
Multinational R&D investment in Turkey, particularly investment in clinical trials, has been quite limited relative to the size of the Turkish pharmaceutical market. Turkish R&D spending amounted to just 0.95…
Over the past six years, Turkey has consistently lowered its drugs prices and guided its companies to greater efficiency. “Reference prices in Turkey are constructed from the lowest price in…
In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning…
Recep Altekin, the general manager of MT Sağlik – market leader in Turkey for blood glucose monitoring systems and diabetes test strips by volume – tells PharmaBoardroom about his company’s impact…
AstraZeneca’s Country President for Turkey discusses their efforts to build scientific leadership in Turkey in line with their global strategy and her hopes for the market access and public-private partnership…
See our Cookie Privacy Policy Here